CTI Announces First Sale of its New Breast Cancer Imaging System; Unique Non-Invasive Advancement Aids Physicians in Diagnosis of Breast Cancer.Business Editors LAYTON, Utah--(BUSINESS WIRE)--June 19, 2000 Computerized Thermal Imaging, Inc. (CTI (Computer Telephone Integration) Combining data with voice systems in order to enhance telephone services. For example, automatic number identification (ANI) allows a caller's records to be retrieved from the database while the call is routed to the appropriate party. ) (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). symbol: COII) announced today the sale of 10 CTI breast cancer imaging systems to a Latin American consortium based in Mexico City Mexico City Spanish Ciudad de México City (pop., 2000: city, 8,605,239; 2003 metro. area est., 18,660,000), capital of Mexico. Located at an elevation of 7,350 ft (2,240 m), it is officially coterminous with the Federal District, which occupies 571 sq mi for $5 million. This consortium, Computerized Thermal Imaging International, and CTI had previously announced an agreement to deploy 100 CTI breast cancer imaging units in Latin America Latin America, the Spanish-speaking, Portuguese-speaking, and French-speaking countries (except Canada) of North America, South America, Central America, and the West Indies. . This initial purchase order was accompanied by a down payment of $1.75 million, with the balance due upon delivery of the systems. "This is a very significant event in our corporate history," stated David Packer, President and COO. "It represents the first sale of our revolutionary breast cancer imaging system and our first significant revenues. This achievement is the result of our unwavering commitment to bring this product to market successfully. Our recent acquisition of Bales Scientific will greatly enhance both production and support. We will now begin production as well as total implementation of the domestic and international product support infrastructure." CTI is seeking FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval for use of its Computerized Thermal Imaging System in the United States as an adjunctive diagnostic test to mammography mammography, diagnostic procedure that uses low-dose X rays to detect abnormalities in the breasts. The early diagnosis of breast cancer made possible by the routine use of mammography for screening women increases a woman's treatment alternatives and improves her and clinical examination for the detection of breast cancer. The test is simple, painless, and involves no radiation, breast compression, electrodes, electrical current, or skin contact. CTI also recently announced evaluation of their technology for new occupational medicine applications. Computerized Thermal Imaging, Inc. is in business to improve the quality of life through superior diagnostics. Information about CTI can be found on the Internet at www.cti-net.com or by calling CTI Public Affairs at (801) 926-1113. Except for historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. In addition to the factors set forth above, other important factors that could cause actual results to differ materially include, but are not limited to technical risks associated with new technology development, government regulatory approvals or continued working capital. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained from time to time in the Company's SEC filings. Copies of these filings may be obtained by contacting the Company or the SEC. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion